ly 274614 has been researched along with ibotenic acid in 1 studies
| Studies (ly 274614) | Trials (ly 274614) | Recent Studies (post-2010) (ly 274614) | Studies (ibotenic acid) | Trials (ibotenic acid) | Recent Studies (post-2010) (ibotenic acid) |
|---|---|---|---|---|---|
| 96 | 0 | 15 | 2,108 | 1 | 211 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leander, JD; Ornstein, PL; Salhoff, CR; Schoepp, DD | 1 |
1 other study(ies) available for ly 274614 and ibotenic acid
| Article | Year |
|---|---|
Neuroprotectant effects of LY274614, a structurally novel systemically active competitive NMDA receptor antagonist.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Binding, Competitive; Brain; Dose-Response Relationship, Drug; Female; Ibotenic Acid; Isoquinolines; Kainic Acid; Male; N-Methylaspartate; Nerve Degeneration; Quisqualic Acid; Radioligand Assay; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate | 1991 |